Animal health company Elanco (NYSE: ELAN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.9% year on year to $1.37 billion. The company expects next quarter’s revenue to be around $1.31 billion, close to analysts’ estimates. Its non-GAAP profit of $0.40 per share was 16.6% above analysts’ consensus estimates.

Is now the time to buy ELAN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Elanco’s first quarter results were met with a positive market reaction, as management pointed to broad-based revenue growth across its pet health and farm animal businesses. CEO Jeffrey Simmons credited the performance to momentum from newly launched products—especially Zenrelia and Credelio Quattro—and share gains in major U.S. and international categories. The company’s execution on its innovation strategy, combined with increased presence at key retail partners, underpinned Elanco’s ability to outperform Wall Street’s revenue and profit expectations. Simmons highlighted, “Our momentum in each of our 4 businesses is evident in market share gains across our global portfolio.”

Looking ahead, Elanco’s upgraded guidance for 2026 is built on the sustained outperformance of its innovation portfolio, continued investment in product launches, and operational efficiency measures under the Elanco Ascend initiative. Management expects further growth as the company expands access to products like Zenrelia and launches Befrena, with Simmons noting, “We are confident in our expectations for high single-digit to low double-digit growth in the back half of the year as our new products continue to gain share.” The executive team cautioned that their guidance reflects a balanced approach, accounting for competitive pressures and macroeconomic factors.

Key Insights from Management’s Remarks

Management attributed the strong quarter to robust demand for its innovation products, expanded retail distribution, and progress in both pet health and farm animal segments.

• Innovation-driven growth: Newer products, particularly Zenrelia and Credelio Quattro, were cited as leading contributors to revenue growth, with Zenrelia reaching blockbuster status in both the U.S. and international dermatology markets. Management emphasized that these products not only gained share but also accelerated the company’s overall growth trajectory.
• Retail channel expansion: Distribution gains at major retailers, including new partnerships with Costco and Dollar General, helped drive high single-digit consumption growth in the U.S. over-the-counter business. These partnerships were identified as meaningful contributors to growth and are expected to support sales in upcoming quarters.
• Farm animal strength: The farm animal division reported double-digit growth across all major species, with poultry and ruminants performing especially well internationally. CEO Simmons attributed this to favorable protein consumption trends and Elanco’s leadership in medicated feed additives.
• Operational and productivity initiatives: The Elanco Ascend program, integrating automation and artificial intelligence, is driving operational efficiencies and margin improvement. CFO Bob VanHimbergen noted that these efforts are expected to yield significant savings, with 75% of benefits impacting gross margin.
• Corporate account momentum: Elanco saw a notable increase in business with veterinary corporate accounts, driven by the appeal of its innovation portfolio. Management highlighted a value-based approach to these accounts, resulting in double the growth rate compared to last year.

Drivers of Future Performance

Elanco’s outlook centers on continued momentum from product innovation, expansion into new retail and international markets, and further operational improvements.

• Innovation product ramp-up: Management expects Zenrelia, Credelio Quattro, and the upcoming Befrena launch to fuel high single-digit to low double-digit growth in the U.S. Pet Health segment in the second half of the year. The company is increasing manufacturing capacity to keep up with demand and is also expanding the Credelio family into international markets.
• Operational efficiency and margin expansion: The Elanco Ascend initiative aims to deliver meaningful gross margin expansion through automation, process improvements, and restructuring, with early benefits already seen in general and administrative expenses. Management believes these efforts will support sustainable profitability even as the company continues to invest in new product launches.
• Competitive and economic headwinds: Management acknowledged ongoing risks from heightened competition, including generics, and potential shifts in consumer spending. These factors are embedded in the guidance, and leadership is taking a balanced approach to investment and pricing to maintain market share and profitability.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be tracking (1) the pace of Zenrelia and Befrena adoption in both U.S. and international veterinary clinics, (2) gross margin improvements driven by the Elanco Ascend productivity program, and (3) the effectiveness of new retail partnerships such as Costco and Dollar General in sustaining OTC growth. Progress on further regulatory approvals and successful global expansion of the innovation portfolio will also be important performance indicators.

Elanco currently trades at $26.17, up from $23 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.